News

The meeting with the FDA concerned the company’s cell-based product for the treatment of ALS. The response received on December 9, 2015 from the FDA represents a summary

"The ADAPT phase 3 trial to evaluate AGS-003 in front line mRCC, the largest global trial ever performed in newly diagnosed, unfavorable risk mRCC patients, continues to progress

If approved, the sNDA would expand the approved use of IBRANCE to reflect findings from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE in combination with fulvestrant versus

The Company is developing TD-1473 as an investigational compound with the potential to treat a range of inflammatory intestinal diseases. TD-1473 is an internally-discovered JAK inhibitor that has

NuSirt also announced the start of enrollment for its Phase 2A clinical trial targeting this disease at nine U.S. research sites. NuSirt Biopharma president and executive chairman of

Reslizumab is a humanized IgG4K monoclonal antibody that binds to anti interleukin 5 (IL-5). The FDA will consider the advisory committee’s recommendation in its review of the biologics

Syncona, an independent subsidiary of the Wellcome Trust, will invest £25m in a Series A financing. UCL professor of haematology Amit Nathwani developed Freeline's next-generation AAV gene therapy

Merck will provide funding and clinical supplies of pembrolizumab for the investigator-initiated study, which is anticipated to start in the first quarter of next year. Imprime PGG is

The acceptance of the NDA by the FDA in its 74-day letter indicates that the application permits a substantive review and there are no issues that have been